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The current review summarizes the pathobiology of nerve growth factor (NGF) and
its cognate receptors during the progression of Alzheimer’s disease (AD). Both
transcript and protein data indicate that cholinotrophic neuronal dysfunction is related
to an imbalance between TrkA-mediated survival signaling and the NGF precursor
(proNGF)/p75NTR-mediated pro-apoptotic signaling, which may be related to alteration
in the metabolism of NGF. Data indicate a spatiotemporal pattern of degeneration
related to the evolution of tau pathology within cholinotrophic neuronal subgroups
located within the nucleus basalis of Meynert (nbM). Despite these degenerative
events the cholinotrophic system is capable of cellular resilience and/or plasticity
during the prodromal and later stages of the disease. In addition to neurotrophin
dysfunction, studies indicate alterations in epigenetically regulated proteins occur within
cholinotrophic nbM neurons during the progression of AD, suggesting a mechanism that
may underlie changes in transcript expression. Findings that increased cerebrospinal
fluid levels of proNGF mark the onset of MCI and the transition to AD suggests
that this proneurotrophin is a potential disease biomarker. Novel therapeutics to treat
NGF dysfunction include NGF gene therapy and the development of small molecule
agonists for the cognate prosurvival NGF receptor TrkA and antagonists against the
pan-neurotrophin p75NTR death receptor for the treatment of AD.
Keywords: Alzheimer, nerve growth factor, mild cognitive impairment, epigenetics, neurotrophin receptors,
biomarker
INTRODUCTION
Alzheimer’s disease (AD) is a progressive and fatal age-associated brain disorder characterized
clinically by memory decline, impairment of activities of daily living, neuropsychiatric symptoms,
and other behavioral disturbance. Prevalence reports indicate that approximately 18 million people
have AD worldwide, with >5.8 million people in the United States (Alzheimer’s Association, 2019).
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The percentage of cases increases twofold with approximately
every 5 years of an increase in age, indicating that 1%
of individuals 60 years of age and approximately 30% of
people 85 years of age will exhibit the disease. Lacking
significant intervention, the number of symptomatic people in
the United States will increase to 13.8 million by midcentury
(2019). The cost of caring for those with AD will exceed 100
billion United States dollars yearly (Christensen, 2007; Wimo,
2007; Wimo et al., 2017). These alarming statistics stress the
overwhelming importance of developing effective treatments for
use in the early or prodromal stages of AD.
PRODROMAL AD
Alzheimer’s disease has an extensive preclinical stage, possibly
as early as 15–20 years before the onset of clinical symptoms
(Sperling et al., 2014) (Figure 1). Mild cognitive impairment
(MCI), a term now synonymous with prodromal AD, is an
intermediate phase between normal brain aging and frank
dementia when neurofibrillary tangles (NFTs) and amyloid-beta
peptide (Aβ) lesions are increased in comparison to those
with no cognitive impairment (NCI) (Guillozet et al., 2003;
Markesbery et al., 2006; Markesbery, 2010). MCI as a clinical
concept was developed from memory clinics, which evaluated
milder demented subjects from longitudinal investigations of
older cohorts who were tested annually for cognitive status.
Such investigations demonstrated that many with earlier, milder
cognitive decline failed to show impairment in two cognitive
domains as required for an NINDS/ADRDA AD diagnosis
(McKhann et al., 1984). These people were defined with an
amnestic disorder and termed amnestic MCI (aMCI) (Petersen
et al., 1999). Although memory clinics suggested that aMCI
was the more common type of MCI leading to AD, it was
evident that this entity comprised a minor but a significant aspect
of this clinical classification. Overall, the clinical diagnosis of
MCI encompasses a heterogeneous population of patients that
includes those with isolated memory problems, classified as single
domain aMCI, while those with a memory deficit and other
cognitive domain impairments are categorized as multi-domain
MCI (mdMCI) (Petersen, 2004; Johnson et al., 2010). Amnestic
MCI cases are at a greater risk of developing AD (Petersen, 2004;
Johnson et al., 2010). A significant proportion of elderly people
clinically diagnosed with NCI or with MCI display amyloid
plaque and NFT pathology similar to that seen in AD, challenging
the pathologically-based concept that these lesions alone hasten
dementia onset (Mufson and Kordower, 1999; Price and Morris,
1999; Markesbery, 2010; Mufson et al., 2016a,b).
CLASSIC AD LESIONS
By the twentieth century, neuropathological investigations
reported the existence of abnormal extracellular plaques in
brains obtained postmortem from older adults with dementia
(Blocq and Marinesco, 1892). The German psychiatrist, Dr. Alois
Alzheimer, treated Auguste Deter, a 51-year old woman, who
presented with signs of paranoia and memory impairment and
died 5 years after diagnosis. At autopsy, her brain appeared
atrophic, with a loss of neurons, and contained NFTs and
senile plaques (SPs). Dr. Emil Kraepelin termed this triad of
features “Alzheimer’s disease.” SPs found in the extracellular
matrix consist of insoluble fibrils of Aβ, produced from a
larger transmembrane amyloid-β precursor protein (APP) by
the successive cleavage by the β-site APP cleaving enzyme 1
(BACE1) and the intramembrane γ-secretase complex (Shoji
et al., 1992; Thinakaran and Koo, 2008). NFTs consist of
intracellular aggregates of hyperphosphorylated tau protein
(Trojanowski et al., 1993; Yoshiyama et al., 2013). Although SPs
and NFTs are considered the defining pathological hallmarks
of AD, Dr. Alzheimer wrote that “. . .the plaques are not the
cause of senile dementia, but only an accompanying feature of
senile involution of the central nervous system” (Alzheimer, 1911).
Despite this statement, the AD research field has been driven by
the “amyloid cascade hypothesis” (Hardy and Selkoe, 2002) and
treatment strategies continue to revolve around the development
of anti-amyloid drugs to remove plaque deposition. However,
virtually all anti-amyloid clinical trials have not met their primary
end-point, the improvement of cognition (Hampel et al., 2015,
2018). This lack of drug efficacy lends support to the concept
that amyloid may be an early biomarker of AD but not necessary
for a clinical decline. More likely AD is a multifaceted polygenic
disease of which amyloid is a partner in the pathogenesis of
this disease. Contrary to the amyloid hypothesis, a large body
of literature suggests the loss of cognition involves the selective
vulnerability of multiple neurotransmitter pathways leading to a
massive cortical disconnection syndrome.
CHOLINOTROPHIC BASAL FOREBRAIN
DEFECTS DURING THE PROGRESSION
OF AD
For over 30 years degeneration of cholinergic basal forebrain
(CBF) neurons, which innervate the entire neocortex and
hippocampus (Figures 2A–D) has been investigated as a key
neurotransmitter system affected early in the disease that may
be a target for AD treatment (Hampel et al., 2018). The
“cholinergic hypothesis” of AD (Bartus et al., 1982) gained
momentum with the finding that acetylcholinesterase inhibitors
(AChEIs) have significant symptomatic effects in AD patients
(Summers et al., 1986) This led to the development of a larger
family of acetylcholinesterase inhibitors (AChEIs) (Hampel et al.,
2018) (Figures 2E–G), which remains one of the few classes
of FDA approved drugs for the treatment of AD (Johannsen,
2006; Mangialasche et al., 2010; Hampel et al., 2018). For
example, the AChEI, donepezil, has been shown to reduce
basal forebrain atrophy within the nucleus basalis of Meynert
(nbM) and the medial septum/diagonal band in prodromal AD,
demonstrating a structural effect (Cavedo et al., 2017) as well as
symptomatic relief.
Recently, there has been a resurgence of interest in the
CBF projection system in the field of early-onset dementia
(Douchamps and Mathis, 2017; Hampel et al., 2018). Imaging
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FIGURE 1 | A schematic illustration depicting the trajectory of the clinical and pathological progression of Alzheimer’s disease (AD). PreMCI, pre-mild cognitive
impairment; MCI, mild cognitive impairment.
studies provide evidence of the importance of dysregulated
basal forebrain circuitry in signaling related to cognitive decline
(Ballinger et al., 2016), dysregulation of the default mode
network (DMN) critical for executive function, episodic memory
(Nair et al., 2018), and propagation of cortical atrophy early
in the evolution of the disease (Schmitz and Nathan Spreng,
2016), and as a pre-symptomatic biomarker for AD (Ho et al.,
2008; Grothe et al., 2012). This renewed interest in cholinergic
cortical projection neurons to the DMN and other cortical
sites during the onset of AD underscores the critical need to
understand the mechanistic factors underlying dysfunction of
this projection system.
NERVE GROWTH FACTOR DURING THE
PROGRESSION OF AD
Since Ramon y Cajal suggested that brain cells require
“special food,” researchers have searched for growth-stimulating
agents that play a role in neuronal survival (Henry, 1998).
Levi-Montalcini and Cohen (Levi-Montalcini, 2000), received
the Nobel Prize for their discoveries showing that the trophic
substance nerve growth factor (NGF) underlies the selective
survival of cultured neurons. They were the first to suggest
the neurotrophic hypothesis of neuronal survival. NGF is a
product of a single gene found on chromosome 1, which gives
rise to a 27 kiloDalton (kDa) and a 35 kDa proNGF precursor
protein (Francke et al., 1983; Edwards et al., 1988), which are
proteolytically cleaved to a mature biologically active peptide
(Edwards et al., 1988; Lee et al., 2001). ProNGF, not mature
NGF, is the primary form found in the human brain (Fahnestock
et al., 2001). NGF binds to its cognate tropomyosin-related
kinase A (TrkA) receptor and the p75 pan-neurotrophin
receptor (p75NTR) (Ibanez, 2002; Chao, 2003; Kaplan and Miller,
2004). NGF binding to TrkA activates downstream survival
pathways by activating Akt (Ulrich et al., 1998) while proNGF
and p75NTR, together with its co-receptors sortilin (Nykjaer
et al., 2004) and neurotrophin receptor homolog-2 (NRH2)
(Murray et al., 2004) activate the c-Jun N-terminal protein
kinase (JNK) related to cellular apoptosis (Nykjaer et al.,
2005) (Figure 3). Clinical trials have shown that NGF has
therapeutic potential to enhance CBF survival and neuroplasticity
in AD (Tuszynski et al., 1990; Tuszynski and Blesch, 2004;
Tuszynski et al., 2015).
NGF AND THE PROGRESSION OF AD
Although for many years it was hypothesized that cholinotrophic
basal forebrain cortical and hippocampal projection neurons
degenerate due to loss of NGF in AD (Hefti and Mash, 1989;
Tuszynski et al., 1990; Smith et al., 1999), studies reported
unchanged (Goedert et al., 1989; Allen et al., 1991; Murase et al.,
1993; Jette et al., 1994), decreased (Hellweg et al., 1998) or
increased (Crutcher et al., 1993; Scott et al., 1995; Fahnestock
et al., 1996; Narisawa-Saito et al., 1996; Hellweg et al., 1998;
Hock et al., 2000) NGF levels using tissue from severe AD
subjects. However, NGF levels were preserved in five cortical
regions (superior frontal, superior temporal, middle temporal,
anterior cingulate, and inferior parietal cortex) and hippocampus
in people who came to autopsy with a clinical diagnosis of MCI,
mild AD, and severe AD (Figure 4) (Mufson et al., 2003). In
contrast, others report an increase in cortical and hippocampal
Ngf mRNA and protein in end-stage AD, where volume loss
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FIGURE 2 | (A) Schematic drawing of the cholinotrophic cortical and hippocampal projection systems. Photomicrographs showing images of cholinotrophic neurons
in an aged control (B), reduction in AD (C) and thioflavin (yellow) tangle-bearing p75NTR neurons (dark blue) (D) in AD. Cartoon showing changes in acetylcholine
(ACh) between a normal (E) and AD (F) and the effect of acetylcholinesterase inhibitors at the cholinergic synapse (G). Ch1, medial septal cholinergic cell group;
Ch2, vertical limb of the diagonal band cholinergic cell group Ch4; nucleus basalis cholinergic cell group and Hip, hippocampus. Red and green arrows indicate
bilateral Ch4 projections; dark blue and light blue arrows indicate septal/diagonal band projections to the hippocampus.
could lead to increased concentrations of NGF per weight or
volume (Crutcher et al., 1993; Jette et al., 1994; Scott et al., 1995;
Fahnestock et al., 1996; Narisawa-Saito et al., 1996; Hellweg
et al., 1998; Hock et al., 2000) or the translation from Ngf
to encoded NGF protein may be compromised or expression
levels differ between AD cases. We reported a wide range of
NGF activity in a cohort ranging from early to late-onset AD
cases and some of the highest and lowest levels of NGF were
seen in end-stage AD cases (Scott et al., 1995), suggesting that
within a given cohort, NGF levels can be differentially affected
by age at disease onset or differences in disease process. In
this study, there was no relationship between cortical choline
acetyltransferase (ChAT) activity, the rate-limiting enzyme for
acetylcholine synthesis, and levels of NGF, nor between reduced
numbers of ChAT- (Gilmor et al., 1999), TrkA- (Mufson et al.,
2000), or p75NTR− (Mufson et al., 2002b) containing neurons in
MCI and mild AD. Moreover, the lack of a correlation between
the apolipoprotein ε4 genotype and NGF levels is interesting,
since ApoE ε3 and ε4 alleles are reported to be associated
with a greater decrease in cholinergic markers in end-stage AD
(Poirier et al., 1995). Although over 90% of the severe AD cases
we examined from the Rush Religious Orders Study (RROS)
contained at least one ApoE ε4 allele, NGF levels did not differ
across the clinical groups evaluated (Mufson et al., 2003). These
observations suggest that ApoE ε4 genotype does not directly
affect the metabolism of NGF.
EXPRESSION OF NGF RECEPTORS
DURING THE PROGRESSION OF AD
Cholinergic basal forebrain neuron function is dependent upon
the binding of NGF to its cognate receptor TrkA, as well
as its pan-neurotrophin p75NTR, which lends support to the
suggestion that dysregulation of NGF and its receptors underlie
cholinergic neuron dysfunction in AD. TrkA receptors and
p75NTR are produced within the perikarya of CBF neurons
and anterogradely transported to the cortex and hippocampus
the sties of NGF production (Schwab et al., 1979). Within
CBF neurons, mature NGF binds to the TrkA receptor,
activating signal transduction pathways that regulate neuronal
survival induced by NGF (Kaplan and Miller, 2004). However,
p75NTR is a positive modulator of NGF/TrkA binding (Kaplan
and Miller, 2004), and exhibits several context-dependent
functions including the stimulation of apoptotic or cell death
pathways (Bamji et al., 1998; Yoon et al., 1998; Frade, 2000;
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FIGURE 3 | Illustration showing NGF related upstream and downstream pathways.
FIGURE 4 | Box plots showing the stability of NGF protein levels with the cortex and hippocampus during the progression of AD. Reproduced from
Mufson et al. (2003).
Friedman, 2000; Lee et al., 2001; Roux and Barker, 2002).
In this regard, the specific downstream effects of p75NTR
are dependent upon its interaction with various receptor
chaperones (Mamidipudi and Wooten, 2002; Nykjaer et al., 2004;
Teng and Hempstead, 2004).
In order to evaluate whether the number of CBF
neurons containing NGF receptors is altered early in the
progression of AD, we examined tissue from RROS subjects
clinically categorized as NCI, MCI, or AD (Gilmor et al.,
1999). Interestingly, the numbers of ChAT-containing
neurons were stable in MCI and mild AD, while TrkA- and
p75NTR-immunoreactive neurons were significantly decreased
compared to NCI, indicating a phenotypic downregulation of
receptors supporting CBF function rather than frank neuronal
degeneration in MCI (Gilmor et al., 1999) (Figure 5). The
phenotypic loss of cholinotrophic markers due to atrophy,
rather than overt cholinergic cell loss, is consistent with
animal model studies of septal cholinergic neuron axotomy
via fimbria-fornix transection and excitotoxicity (Hefti, 1986;
Williams et al., 1986; Ginsberg and Martin, 1998). In AD,
reduced cortical TrkA levels positively correlated with lower
cognitive performance as assessed by the Mini-Mental State
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FIGURE 5 | Histograms showing the differential reduction in cholinergic, TrkA and p75NTR immunoreactive neurons during the progression of AD. A1- C1.
Photomicrographs of dual labeled nucleus basalis neurons showing phenotypic downregulation of p75NTR (dark blue) compared to ChAT (pink) positive neurons
between no cognitive impairment (NCI), mild cognitive impairment (MCI) and AD. Note the loss of p75NTR immunoreactive staining of ChAT-positive cells in MCI and
AD (open arrows). Black arrow indicates dual stained neuron in AD (C1), ∗ and ∗∗ indicate p < 0.05 and 0.01, respectively.
Exam (MMSE) (Counts et al., 2004), suggesting that decreased
nbM and cortical NGF receptor protein levels may mark the
early onset of AD.
CORTICAL proNGF LEVELS DURING
THE PROGRESSION OF AD
Alterations in proNGF, the NGF precursor protein, has
received extensive study in clinical pathological investigation of
components of the cortical DMN, which includes frontal cortex,
posterior cingulate, precuneus, superior temporal cortex (Perez
et al., 2015), and the hippocampus (Mufson et al., 2012b), which
contribute to cognitive dysfunction during the progression of
AD (Sperling et al., 2014). ProNGF isolated from AD cortex
induces apoptosis in neuronal cell cultures by interacting with
p75NTR via a mechanism dependent upon γ-secretase shedding
of the receptor, whereas proNGF isolated from control brain
does not activate apoptosis (Pedraza et al., 2005). ProNGF levels
are increased in the lateral parietal cortex of patients who
died with a clinical diagnosis of MCI or mild AD compared
to those with NCI (Peng et al., 2004). In contrast, precuneus
proNGF levels were stable until end-stage AD (Perez et al., 2015),
similar to that of the frontal cortex (Fahnestock et al., 2001,
2004; Podlesniy et al., 2006) and hippocampus (Al-Shawi et al.,
2008; Mufson et al., 2012b), all of which suggest alterations
of proNGF in the diseased brain. Western blotting found no
changes in the levels of TrkA, p75NTR and the co-receptor, sortilin
within the precuneus (Perez et al., 2015), and hippocampus
(Mufson et al., 2010) across clinical groups. ProNGF binds with
a higher affinity to p75NTR, which is enhanced in the presence
of sortilin to induce apoptosis (Lee et al., 2001; Nykjaer et al.,
2004; Pedraza et al., 2005; Al-Shawi et al., 2008). Homeostatic
regulation of NGF receptors, combined with the binding of
proNGF to TrkA (albeit with less affinity than mature NGF),
results in the activation of downstream pathways involved in
CBF neuron function (Fahnestock et al., 2001, 2004) as well as
the induction of neurotrophic activity via the binding with less
affinity to the TrkA receptor (Fahnestock et al., 2001, 2004). The
finding that p75NTR levels remain stable in the precuneus and
other cortical regions (Counts et al., 2004; Mufson et al., 2012b)
during the onset of AD may be related to the demonstration
of a de novo appearance of p75NTR cortical neurons in AD
(Mufson and Kordower, 1992).
The pro-apoptotic effect(s) of p75NTR-mediated proNGF
signaling is dependent on interactions with p75NTR and sortilin,
a Vps10p domain trafficking protein that acts as a cell surface
co-receptor with p75NTR to mediate proNGF-activated cell
death. This family of receptors is gaining importance, due
to its potential involvement in AD (Nyborg et al., 2006).
Sortilin activates p75NTR-induced apoptosis following proNGF
treatment (Nykjaer et al., 2004), suggesting a role in cell death
(Mamidipudi and Wooten, 2002; Roux and Barker, 2002).
Blocking this binding event precludes binding of proNGF
to p75NTR and subsequent cell degeneration (Bronfman and
Fainzilber, 2004; Kaplan and Miller, 2004; Nykjaer et al., 2004;
Teng et al., 2005). It is possible that p75NTR signaling in
response to proneurotrophins depends upon the identity and
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efficacy of the bound co-receptor. Notably, cortical levels of
sortilin remain stable, similar to p75NTR during the progression
of AD. Perhaps pro-survival or pro-apoptotic signaling in
CBF neurons is dependent upon changes in the stoichiometry
of TrkA, p75NTR, the availability of select co-receptors, and
the physiological role of proNGF within different milieus
during the early stage of AD. Shifting the balance of these
factors may change the response that proNGF binding activates
within CBF neurons during the progression of AD (Figure 6).
Defining these interactions will be key to the development
of neurotrophic strategies for dementia (Bruno et al., 2004;
Longo et al., 2007). If proNGF binds p75NTR in vivo and
induces apoptosis (Lee et al., 2001; Nykjaer et al., 2004),
it will be crucial to develop drugs that block proNGF
binding to p75NTR. In contrast, if proNGF binds with TrkA
to induce cell survival (Fahnestock et al., 2004), then the
development of drugs that enhance this interaction could provide
neuroprotection in AD.
NGF METABOLIC PATHWAYS DURING
THE PROGRESSION OF AD
Defects in the metabolic pathways regulating the maturation
and degradation of the NGF/proNGF complex may play a
key role in CBF dysfunction. Recently, a protease cascade,
which converts proNGF to mature mNGF and degrades
mNGF in the extracellular space by the coordinated activity of
plasminogen, tissue plasminogen activator (tPA), neuroserpin,
matrix metalloproteinase 9 (MMP-9) and tissue inhibitor
of matrix metalloproteinase 1 (TIMP-1) was shown to be
defective in AD (Bruno and Cuello, 2006). In this regard,
the upregulation of MMP-9 protein levels and activity were
reported in the frontal and parietal cortex in MCI and AD,
which was inversely associated with cognitive performance
(Bruno et al., 2007), and may drive changes in NGF/proNGF
activity (Figure 7). We suggest that increased proMMP-9 and
MMP-9 compromises NGF support of CBF neurons during
the transition from NCI to MCI (Figure 7). Interestingly, a
similar increase in cortical proNGF (Iulita et al., 2014) and
reduction in TrkA-positive CBF neurons (Sendera et al., 2000)
has been reported in Down syndrome (DS), suggesting an
overlap in NGF neurotrophic dysregulation in these disorders.
Both AD and DS cases display cortical SP and NFT pathology
and develop dementia by midlife (Mann and Esiri, 1989),
further connecting these neurological conditions. It has been
suggested that levels of metalloproteinases (MMPs) in blood,
urine, and cerebrospinal fluid (CSF) may act as potential
biomarkers for AD (Zucker et al., 1999; Lorenzl et al., 2003,
2008). It is of interest to examine whether or not MMPs are
dysregulated in the precuneus, allowing for the stable metabolic
NGF/proNGF complex regulation early in AD. Notably, proNGF
levels were not associated with increased soluble Aβ1−42 or
fibrillar Aβ [3H] Pittsburgh Compound B (PiB) binding,
but instead with compact/cored 6-CN-PiB– positive plaques
in AD (Perez et al., 2015), suggesting that fibrillar deposits
of Aβ, rather than its soluble forms, may play a role in
the upregulation of proNGF we found in the precuneus.
Neurodegeneration is a consequence of Aβ1−40 binding to
p75NTR (Knowles et al., 2009) and CBF perikarya when Aβ
oligomers are delivered to the brains of wild type but not
p75NTR deficient mice (Simmons et al., 2014). Interestingly,
CBF degeneration was halted following the depletion of the
neurotrophin-binding domain of p75NTR in a mouse model of
FIGURE 6 | Cartoon demonstrating the shift from cell survival to cell death related to NGF activity during the progression of AD. (A) ProNGF/TrkA complex activates
cell survival mechanisms, which is facilitated by the co-expression of p75NTR on the cell surface in the healthily aged brain. ProNGF also creates a signaling complex
by simultaneously binding to sortilin a co-receptor for proNGF. (B) In AD, elevated cortical proNGF in the face of reduced TrkA enhances binding of proNGF to
p75NTR /sortilin complex. Since sortilin acts as a molecular switch governing a p75NTR mediated pro-apoptotic signal, increased proNGF triggers cell death in the
face of decreased TrkA. Modified from Mufson et al. (2012a).
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FIGURE 7 | Diagram illustrating the effect of an increase of proMMP-9/MMP-9 has upon the ability of NGF to support cholinotrophic basal forebrain neurons during
the progression of AD.
AD (Knowles et al., 2009). These findings suggest that p75NTR
signaling is involved in Aβ-induced degeneration and implicate
it as an AD therapeutic target.
HIPPOCAMPAL proNGF AND
DOWNSTREAM PATHWAYS DURING
THE PROGRESSION OF AD
The hippocampus is a part of the mesial temporal lobe memory
circuit. It develops extensive NFTs but lesser amyloid pathology
in the early stages of AD (Hyman et al., 1984, 1990; Braak
and Braak, 1991; Arriagada et al., 1992) and receives a major
cholinergic input from the medial septal and vertical limb
of the diagonal band neurons (Mesulam et al., 1983). Since
these septohippocampal cholinergic projection neurons are also
dependent upon NGF and its cognate receptors for their survival
and degenerate in AD, studies were performed to determine
alterations in the hippocampal NGF/proNGF system. Western
blot analysis revealed a significant increase in hippocampal
proNGF levels in AD but not MCI (Mufson et al., 2012b)
in contrast to the neocortex (Bruno et al., 2009; Perez et al.,
2015). Of interest is the observation of a significant reduction
in TrkA protein levels in MCI hippocampus compared to NCI
and AD and a return to NCI levels during the transition from
MCI to AD (Mufson et al., 2012b) (Figure 8). The decrease in
TrkA in the face of stable proNGF early in AD may enhance
proNGF/p75NTR/sortilin/NRH2 binding, ultimately shifting the
balance from pro-survival to pro-apoptotic signaling in the
hippocampus (Figure 8). The upregulation of hippocampal TrkA
levels is yet another example of human brain resilience (Mufson
et al., 2016a,b) to slow disease progression.
Nerve growth factor and proNGF activate numerous
downstream cell survival and apoptotic signaling pathways,
respectively (Figure 8). The cell survival protein Erk, which is
activated by TrkA phosphorylation, activates nuclear effectors
involved in gene transcription (Zhu et al., 2001). Precuneus
(Perez et al., 2015) and hippocampal (Mufson et al., 2012b)
levels of total Erk, phospho-Erk, and phospho-Erk/Erk ratio
are unchanged between NCI, MCI, and AD. In contrast,
stress-activated kinase phospho-JNK, and the ratio of
phospho-JNK to JNK were significantly increased in the
AD precuneus (Figure 8) (Perez et al., 2015) and hippocampus
(Mufson et al., 2012b), whereas total JNK levels were stable
similar to the AD hippocampus (Mufson et al., 2012b). Bcl2
a component of the JNK signaling pathway involved in
the activation of apoptotic enzymes was upregulated in the
precuneus in AD but not MCI (Perez et al., 2015). Of particular
interest was the finding that phospho-JNK and the density of
AT8 tau-positive NFTs and neuropil threads (NTs) are positively
related during the onset of AD, supporting the observation that
JNK activation mediates tau phosphorylation at Ser202/Thr205
(AT8 site) (Goedert et al., 1997; Reynolds et al., 1997). Therefore,
the activation of JNK pro-apoptotic signaling may play a role in
episodic memory impairment in AD.
CHOLINOTROPHIC BASAL FOREBRAIN
NEURON GENE EXPRESSION DURING
AD PROGRESSION
The identification of the genetic signature of ‘selectively
vulnerable’ CBF neurons compared to relatively spared neurons
during the onset of AD is crucial for the development of
transcriptionally aided drug design to target therapeutics to
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FIGURE 8 | Schematic diagrams showing alteration in hippocampal neurotrophic protein levels during the progression of AD. Reproduced from Mufson et al. (2015).
intervene with the onset of AD. A transcriptionally-driven
therapeutic approach may be more likely to preserve brain
connectomes including the NGF dependent CBF system that
plays a key role in the pathogenesis and onset of dementia,
especially during early stages of the disease process (Mufson
et al., 2012a). Studies comparing gene expression profiles of
CBF neurons identified by p75NTR (Mufson et al., 1989)
display a dysregulation of select synaptic-related markers (e.g.,
downregulation of synaptophysin and synaptotagmin 1 among
others), protein phosphatases/kinases (e.g., downregulation of
protein phosphatases 1 and 2 subunits and upregulation of
cyclin-dependent kinase 5) along with endosomal-lysosomal
markers (e.g., upregulation of lysosomal markers cathepsin D,
rab4, rab5, and rab7) in MCI and AD compared to age-matched
NCI subjects (Ginsberg et al., 2006a,b, 2010; Counts et al., 2011).
Moreover, significant downregulation of TrkA, TrkB, and TrkC
was seen in single CBF neurons microaspirated from the nbM
of MCI and AD compared to NCI (Ginsberg et al., 2006b)
(Figure 9A), consistent with observations in another vulnerable
cell type, hippocampal CA1 pyramidal neurons (Ginsberg et al.,
2000, 2010). These findings revealed an intermediate reduction
in MCI with the greatest decrement in AD compared to NCI.
Moreover, expressed sequence tagged cDNAs (ESTs) [i.e., ESTs
targeted to both the extracellular domain (ECD) and tyrosine
kinase (TK) domains of Trk receptors] were downregulated.
A ‘step down’ dysregulation of Trk expression, may in part,
underlie CBF neuron demise associated with the clinical
presentation of AD. Supporting this concept is the finding that
downregulation of TrkA was associated with several measures
of cognitive decline, including the MMSE, a composite global
cognitive score (GCS), Episodic, Semantic, Working Memory,
Perceptual Speed, and Visuospatial domains as well as Braak
NFT stage and neuritic plaque (NP) load within the basal
forebrain and hippocampus (Ginsberg et al., 2006b, 2019).
Hence, Trk gene expression defects may provide a molecular
marker for the transition from MCI to frank AD (Ginsberg
et al., 2019). In contrast, p75NTR transcript levels were stable
in CBF neurons across the clinical diagnostic groups (Ginsberg
et al., 2006b), which was an intriguing finding compared to the
significant reduction of p75NTR-immunopositive nbM perikarya
in MCI and AD compared to NCI (Gilmor et al., 1999). The
discrepancy between p75NTR protein and transcript expression
in CBF neurons suggests a disconnection between mRNA
transcription and protein translation during disease onset. CBF
single population observations in postmortem human brain
tissues suggest a relative selectivity in the alteration of the family
of cognate NGF receptors during the progression of AD, and that
neurotrophic deficits precede or occur during the earliest stages
of cognitive decline and neuropathology.
CHOLINOTROPHIC NEURON TAU
PATHOLOGY DURING THE
PROGRESSION OF AD
Coincident with altered neurotrophic factor dysfunction during
disease progression, CBF neurons also develop intracellular tau
inclusions that appear as globose NFTs as well as NTs in
MCI and AD (Sassin et al., 2000; Mesulam et al., 2004; Wu
et al., 2005; Vana et al., 2011). The human brain contains
three isoforms of tau with three tandem repeats (3Rtau; Mapt1,
Mapt3, and Mapt5) and three tau isoforms with four tandem
repeats (4Rtau; Mapt2, Mapt4, and Mapt6). Custom-designed
microarray evaluation of CBF neurons did not reveal changes
in any of the six tau transcripts between AD, MCI and
NCI subjects (Ginsberg et al., 2006a). However, a significant
shift in the ratio of 3Rtau/4Rtau ratio was observed with
a decrease in 3Rtau expression relative to 4Rtau levels for
all tau transcripts. Tau transcript data suggest a fluctuation
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FIGURE 9 | Findings derived from single cholinotrophic neuron profiling during
the progression of AD. (A) Heatmap demonstrating downregulation of Ntrk1
(TrkA), Ntrk2 (TrkB), and Ntrk3 (TrkC) {both the extracellular domain (ECD) and
the tyrosine kinase domain (TK)} (asterisk), but not Ngfr (p75NTR) during the
progression of dementia. Trk gene expression in MCI is intermediate to AD,
indicating a step-down effect from NCI to MCI to AD. (B) Heatmap of the
relative expression profiles for select neurotrophin transcripts in pS422+ nbM
neurons. No differences in Trk receptors or Ngfr were found in MCI or AD
compared to NCI. (C) Downregulation of Trk receptors was found in pS422+
nbM neurons compared to unlabeled control neurons. Downregulation of Ngfr
was associated with the neoepitope TauC3. Key: (a) unlabeled > pS422,
p < 0.001; (b) unlabeled > pS422, p < 0.01; (c) pS422 > pS422+/TauC3+,
p < 0.01. (A) Adapted with permission from Ginsberg et al. (2006b). (B,C)
Adapted with permission from Tiernan et al. (2018a).
in gene dosage for 3Rtau and 4Rtau within CBF neurons
in MCI and AD, which was not seen in normal aging
(Ginsberg et al., 2006a).
Single neuron expression profiling investigations have
addressed the extent to which levels of transcripts encoding
neurotrophin receptors are altered in individual nbM neurons
labeled for the pretangle marker pS422+, the late stage
caspase-cleaved tau marker TauC3+ or pS422/TauC3+
compared to unlabeled neurons obtained from NCI, MCI,
and AD cases provided by the RROS (Tiernan et al., 2018a).
Quantitative analyses compared transcript signal intensities
between clinical stages or between tau neuronal phenotypes.
Comparison of transcript expression in pS422+ nbM neurons
microaspirated from each clinical stage revealed no statistical
differences (Figure 9B). However, when analyzed independent
of clinical diagnosis, expression levels of key genes regulating
neurotrophin receptor expression were altered as classified
by a phenotypic transition from unlabeled to pS422+ to
pS422+/TauC3+ to TauC3+ in nbM neurons (Figure 9C).
Compared to unlabeled, pS422+ nbM neurons showed
a significant downregulation of six mRNAs encoding the
intracellular TK and extracellular ECD domains of the
neurotrophin receptors TrkA (Ntrk1 TK, 50% downregulation;
Ntrk1 ECD, 53%), TrkB (Ntrk2 TK, 45%; Ntrk2 ECD, 42%),
and TrkC (Ntrk3 TK, 38%; Ntrk3 ECD, 35%) (Figure 9C).
In addition, we found that these same transcripts are
significantly downregulated in neurons containing the early
pretangle tau antibody Tau Oligomeric Complex 1 (TOC1)
(Counts, unpublished observations), lending support to
the hypothesis that neurotrophic dysfunction occurs before
frank NFT formation.
In contrast, transcript levels of the mRNA encoding
the pan-neurotrophin receptor p75NTR (Ngfr) were not
decreased until the appearance of TauC3. This expression data
complements our stereologic finding demonstrating that TauC3
and p75NTR did not co-localize within the CBF at the protein
level (Mufson et al., 2002b; Vana et al., 2011). Prior studies
reported that Trk receptors expression levels are downregulated
in nbM neurons in MCI and AD relative to NCI (Ginsberg et al.,
2006b). On the other hand, it was found that Ntrk transcripts
were downregulated by the phenotypic transition from nbM
non-labeled to pS422+ neurons, whereas no difference was
found in Ntrk expression in pS422+ neurons from NCI, MCI,
and AD cases (Figure 9C).
We previously performed antibody imunostaining for TOC1
(Patterson et al., 2011; Ward et al., 2013) and p75NTR to
quantify pretangle tau oligomeric assemblies, which most likely
are the more neurotoxic species of tau (Berger et al., 2007;
Maeda et al., 2007; Kopeikina et al., 2011; Lasagna-Reeves
et al., 2012; Sahara et al., 2013) within CBF neurons during the
progression of AD (Tiernan et al., 2018b). Here the number of
p75NTR+/TOC1+ nbM neurons progressively increased from
NCI to MCI to AD, whereas single TOC1+ nbM neurons
were lower in NCI and MCI but increased in AD. A sub-
analysis of p75NTR+, p75NTR+/TOC1+, and TOC1+ nbM
neurons in NCI cases with a low Braak score (Stages I–
II) compared to a high Braak score (Stages III–V) revealed
a significant increase in the number of p75NTR+/TOC1+
dual-immunolabeled neurons in NCI-high pathology compared
to NCI-low pathology cases. The reduction of p75NTR+
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nbM neurons was associated with poorer GCS and MMSE
performance test scores. TOC1 primarily co-localized with
pS422 in NCI, but the transition to MCI and AD was
marked by a shift from TOC1+/pS422+ toward triple-labeled
TOC1+/pS422+/MN423+ neurons, implying a specific, linear
order of epitope occurrence in nbM cholinotrophic neurons
during disease progression. This arrangement suggests that
aberrant phosphorylation primes the tau protein toward
additional phosphorylation and conformational events (Luna-
Munoz et al., 2007; Bertrand et al., 2010) that facilitates
oligomerization (Iqbal et al., 2013). Given the findings that
prefibrillar tau pathology is related with molecular and cellular
alterations within nbM neurons (Tiernan et al., 2016, 2018b), the
appearance of prefibrillar oligomeric tau likely precedes cell loss.
Evidence implicating tau pathology as a driver of neurotrophic
dysfunction is seen in tau transgenic mice and tau-transfected
neuronotypic cells, which display a downregulation of the trophic
substance brain-derived neurotrophic factor (BDNF) (Rosa et al.,
2016). On the other hand, NGF regulates tau turnover (Sadot
et al., 1996) and post-translational modifications including
phosphorylation, cleavage, and ubiquitination (Nuydens et al.,
1997; Shelton and Johnson, 2001; Babu et al., 2005; Amadoro
et al., 2011), suggesting that neurotrophic abnormalities initiate
tau pathology within CBF neurons (Canu et al., 2017). Moreover,
the reduced microtubule-binding capacity of tau and/or the
somatodendritic accumulation of tau may contribute to axonal
degeneration and associated NGF/TrkA signaling dysregulation
(Mufson et al., 2002a; Schindowski et al., 2008). Additionally,
proNGF induces tau hyperphosphorylation in vitro via the
enhanced activity of GSK3β (Shen et al., 2018). Based on these
collective results future analysis of the potential interactions
between aberrant tau metabolism and disrupted neurotrophic
signaling in cholinotrophic nbM neurons (Capsoni et al., 2000).
CHOLINOTROPIC EPIGENETIC
ALTERATIONS DURING THE
PROGRESSION OF AD
Histone acetylation and deacetylation are also involved in
CBF neuron function via their regulation of ChAT (Aizawa
and Yamamuro, 2010; Aizawa et al., 2012; Bekdash, 2016)
indicating a potential role for epigenetics in neuronal
selective vulnerability in AD. Evidence is growing that
histone deacetylases (HDACs), epigenetic enzymes with
deacetylase activity, located within the nucleus and cytoplasm
of neurons play a role in AD pathogenesis (Ding et al., 2008;
Guan et al., 2009; Xu et al., 2011; Cook et al., 2012; Graff
et al., 2012). Several HDACs are related with cellular events
dysfunctional in AD, including endoplasmic reticulum stress
(HDAC4) (Shen et al., 2016), autophagy (HDAC6) (Pandey
et al., 2007), mitochondrial transport (HDAC6) (Chen et al.,
2010), tau hyperphosphorylation (HDAC6) (Ding et al.,
2008) and Aβ and tau accumulation (SIRT1) (Julien et al.,
2009; Lalla and Donmez, 2013). However, whether epigenetic
dysregulation occurs in cholinotrophic nbM neurons remains
under-investigated in AD.
Of the HDACs, HDAC2 has received extensive
investigation due to a role in the modulation of transcripts
involved in cognition via chromatin plasticity regulation
(Dawson and Kouzarides, 2012; Graff and Tsai, 2013; Volmar and
Claes, 2015). In this regard, a clinicopathological investigation
revealed alterations in HDAC2-immunoreactive (ir) nuclei
within nbM neurons during the onset of AD (Mahady et al.,
2019). This study revealed that normally rounded HDAC2-ir
nbM nuclei appeared ovoid, flattened, and eccentrically located
within the soma in MCI, mild AD (mAD) and severe AD (sAD)
(Figures 10A–H). HDAC2 nuclear intensity was significantly
reduced in sAD compared to the other clinical groups examined
(Figures 10D,H). Moreover, HDAC2-ir nuclear intensity was
significantly reduced in mAD compared to the NCI and MCI
groups (Figure 10I). This study further demonstrated that
HDAC2 nbM nuclear intensity was not significantly different in
NCI and MCI. The sAD nuclear area was significantly smaller
than observed in NCI, MCI, and mAD (Figure 10J). In mAD,
HDAC2-ir nuclei displayed significantly smaller area compared
to NCI. HDAC2-ir nuclear intensity was found to correlate with
working memory and a GCS (Mahady et al., 2019). A decline in
the number of nbM p75NTR immunoreactive neurons decreased
across disease stages and was related to a reduction in HDAC2
nuclear immunoreactivity (Mahady et al., 2019). Similarly, a
reduction in HDAC2 nuclear immunoreactivity was inversely
related to an increase in the number of AT8 pretangle-bearing
nbM neurons. Quantitation of the intensity of HDAC2 nuclei
revealed a significant reduction in non-tangle bearing p75NTR-
positive neurons in mAD and sAD compared to NCI and
MCI. NbM neurons triple-labeled for p75NTR, the pretangle
maker AT8 or late-stage tau epitope, TauC3, displayed an even
larger decrease in HDAC2 immunoreactivity in AD compared
to non-tangle bearing p75NTR neurons at each disease stage
(Mahady et al., 2019). Within-group analysis indicated HDAC2-
ir was highest in non-tangle bearing cholinergic perikarya
in each clinical group (Mahady et al., 2019). Interestingly,
HDAC2 nuclear immunoreactivity was further decreased in
HDAC2/AT8/Thioflavin-S or HDAC2/TauC3/Thioflavin-S
neurons in MCI and mAD. These findings suggest that a
reduction in HDAC2 expression occurs before the onset of
fibrillar tau pathology and that this alteration is exacerbated
by phosphorylated and conformational tau epitopes in nbM
neurons during the progression of AD. Although ChAT mRNA
expression and protein levels are epigenetically modulated
by hyperacetylation of the core promoter region of the ChaT
transcript (Aizawa et al., 2012), decreased HDAC2 nuclear
levels were found within cholinergic nbM neurons in MCI,
but significantly decreased ChAT nbM protein levels were
seen only in AD (Mahady et al., 2019). These phenomena
suggest that HDAC2 nuclear protein downregulation does
not alter neuronal ChAT activity early in the disease process.
Immunohistochemical analysis of HDACs in cortical cholinergic
nbM projection sites demonstrated differential regional findings.
For instance, although HDAC1 and HDAC2 are reduced in
AD entorhinal cortex (Mastroeni et al., 2010), HDAC2, but
not HDAC1 or HDAC3, are increased in hippocampal and
entorhinal cortex neurons in AD compared to HDAC2 in control
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FIGURE 10 | Photomicrographs of single HDAC2 (A–D) and HDAC2 and cresyl violet dual stained (E–H) nucleus basalis neurons. Nuclei positive for HDAC2 lost
their rounded shape and were displaced to the periphery of the soma in the MCI, mAD, and sAD groups. (I) Box plots showing HDAC2-ir was significantly
decreased in mAD compared to NCI and MCI (p < 0.001), and sAD compared to NCI, MCI, and mAD (p <0.001). (J) Box plots showing area of HDAC2-ir nuclei
was significantly decreased in mAD compared to NCI (p = 0.03) and in sAD compared to NCI (p < 0.001), MCI (p < 0.001), and mAD (p = 0.04) groups. Circles in
box plots indicate outliers. ∗p < 0.05; ∗∗p < 0.001. Scale bar: 10 µm. Reproduced from Mahady et al. (2019).
subjects (Graff et al., 2012). Western blots of frontal cortex
revealed significant increases in HDAC1, HDAC3, HDAC4, and
HDAC6 in MCI and mAD compared to NCI whereas HDAC2
levels remained stable (Mahady et al., 2018). These findings
suggest that differential epigenetic regulation occurs across brain
regions affected in AD.
CHOLINOTROPHIC BIOMARKERS FOR
THE PROGRESSION OF AD
As discussed above, protein levels of proNGF are increased in
postmortem neocortex (Peng et al., 2004) and hippocampus
(Mufson et al., 2012b) of subjects who died with a clinical
diagnosis of MCI or mild AD compared to NCI, respectively,
which correlated with poorer antemortem cognitive test scores
(Peng et al., 2004; Mufson et al., 2012b). These observations
initiated an investigation of whether altered CSF levels of proNGF
mark a transition from NCI to MCI and AD. Ventricular CSF
(vCSF) was obtained postmortem from RROS participants and
premortem lumbar CSF was collected from subjects clinically
diagnosed as CDR 0 (no dementia), CDR 0.5 (MCI or very
mild AD), or CDR 1 (mild AD) at the Washington University
Knight AD Research Center (Counts et al., 2016). Quantitative
western blotting of vCSF revealed a significant (50%) increase
in proNGF levels in aMCI compared to NCI and a 70%
increase in AD compared to NCI, which displayed a significant
inverse relationship between increasing vCSF proNGF levels
and cognitive deterioration (Counts et al., 2016). Lumbar CSF
proNGF levels were significantly (30%) increased in CDR 0.5
and CDR 1 compared to CDR 0 cases. Although no difference in
levels of Aβ1−42, total tau, phospho-tau, or phospho-tau/Aβ1−42
was found between groups, the ratio of total tau/Aβ1−42 levels
was 50% higher in CDR 1 compared to CDR 0 subjects.
Ratios were calculated for proNGF/Aβ1−42, proNGF/total tau,
and proNGF/phospho-tau to determine if the inclusion of CSF
proNGF levels improved the reliability of these biomarkers.
Interestingly, proNGF/Aβ1−42 levels were 50% higher in CDR
0.5 and CDR 1 compared to CDR 0, whereas proNGF/total
tau and proNGF/phospho-tau were unchanged between groups,
suggesting the inclusion of proNGF as a candidate biomarker will
improve the diagnostic probability needed to identify people in
the preclinical or prodromal stages of AD.
NGF THERAPY AS A TREATMENT
STRATEGY FOR AD
Evidence derived from studies employing NGF as a treatment
strategy to rescue the cholinotrophic cortical projection system
has revealed some promising results regarding prevention of
CBF neuron atrophy and a correction of behavioral deficits
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resulting from experimental damage or normal aging (Hefti,
1986; Williams et al., 1986; Hartikka and Hefti, 1988; Hatanaka
et al., 1988; Nabeshima et al., 1994; Burgos et al., 1995; Charles
et al., 1996; Humpel and Weis, 2002). This evidence led to the
concept that treatments that facilitate NGF would be beneficial
in reversing cholinotrophic dysfunction in AD. However,
examination of studies of early NGF systemic administration
showed several weaknesses including bioavailability of
the neurotrophin to reach target neurons, unregulated
neurotransmitter release, hyperinnervation, sprouting of
neurons, sympathetic stimulation, induction of antibodies,
cachexia, and hyperalgesia (Sramek and Cutler, 1999; Jonhagen,
2000; McArthur et al., 2000; Apfel, 2001). However, after further
testing in rat and non-human primate animal models (Gnahn
et al., 1983; Hefti, 1986; Gage et al., 1989, 1990; Hefti et al.,
1989; Higgins et al., 1989; Tuszynski et al., 1990, 1991, 1996;
Blesch and Tuszynski, 1995) and taking into account past failures
(e.g., poor drug delivery and unwanted systemic side effects),
a Phase I clinical trial was undertaken to determine the utility
of ex vivo NGF gene therapy for AD (Tuszynski et al., 2005).
The goal was both to protect cholinotrophic neurons within
the nbM from degeneration as well as augment the function of
remaining cholinergic neurons by intracranial delivery of human
NGF. During clinical trials, patients with AD, underwent NGF
transcript therapy using ex vivo or in vivo gene transfer directed
at the cholinergic neurons within the nbM. Degenerating nbM
neurons were found to respond to NGF, with axonal sprouting
toward the NGF source (Figure 11). Participants that had
unilateral gene transfer displayed neuronal hypertrophy in the
NGF-treated cholinergic nbM.
Moreover, patients that sustained adeno-associated viral
vector (serotype 2)-mediated NGF gene transfer, displayed
activation of cellular signaling and functional markers.
Interestingly, nbM neurons that exhibited pathologic tau
and those that were tau immunonegative both expressed NGF,
indicating that tangle-bearing neurons can be infected with
therapeutic genes, which activate cell signaling. No adverse
effects related to NGF treatment were found in these studies. In
summary, these findings revealed that degenerating neurons can
respond to NGF with axonal sprouting, cell hypertrophy, and
activation of functional markers. These studies demonstrated
that NGF-induced sprouting persisted for 10 years post NGF
gene transfer and that this therapy appears safe over long periods
of time (Tuszynski et al., 2015). It should be kept in mind
that these studies were not double-blind, placebo-controlled
clinical trials. Further clinical investigation of gene therapy
approaches is warranted.
SMALL MOLECULE NEUROTROPHIN
COMPOUNDS FOR TREATMENT OF AD
Small molecule partial agonist and antagonist activators of
NGF receptors have been considered for the treatment of AD
(Skaper, 2008). For example, a high-throughput screening assay
of small-molecule agonists for TrkA identified gambogic amide,
an alkaloid used in traditional Chinese medicine as a possible
candidate (Jang et al., 2007). Gambogic amide binds selectively
to TrkA (but not TrkB and TrkC), phosphorylates TrkA tyrosine
residues, and activates the Akt and Erk TrkA-mediated NGF
signaling pathways. Gambogic amide has been demonstrated to
ameliorate excitotoxic damage and promote neurite outgrowth
in PC12 cells and reduce kainic acid neuronal induced cell death
in mice (Jang et al., 2007).
Several lines of evidence also point to the modulation of
degenerative signaling promoted by p75NTR as a potential
therapeutic target for AD. Through either its constitutive
activity in the unliganded state, or via that stimulated by its
proneurotropin (proNT) ligands, p75NTR promotes degenerative
signaling mechanisms including activation of JNK, caspase,
and RhoA (Casaccia-Bonnefil et al., 1996; Harrington et al.,
2002; Troy et al., 2002; Ibanez and Simi, 2012; Coulson and
Nykjaer, 2013) each of which likely contributes to AD-related
degeneration (Figure 12). Crossing various AD mouse models
with a p75NTR knockout mouse construct results in reduced
neuronal degeneration (Sotthibundhu et al., 2008; Knowles et al.,
2009; Murphy et al., 2015). Multiple studies have identified
genetic polymorphisms in the genes encoding p75NTR, proNGF,
proBDNF, or p75NTR co-receptors including sortilin and SorCS2
that mediate proNT binding associated with increased AD risk
(Cozza et al., 2008; Di Maria et al., 2012; Anastasia et al., 2013;
Reitz et al., 2013; Andersson et al., 2016; Matyi et al., 2017). The
first small molecule ligands found to interact with p75NTR and
modulate its signaling were identified using an in silico screening
strategy based on synthetic peptides modeled on the loop I
domain of NGF and mutational analyses of neurotrophin ligands
(Massa et al., 2006). Two prototype small molecule compounds,
LM11A-31 and LM11A-24, were found to prevent neuronal
FIGURE 11 | (A) Nerve growth factor (NGF) immunolabeling shows the site of NGF gene delivery in the human nucleus basalis of Meynert (arrowhead) under the
anterior commissure (ac). Scale bar = 325 µm. The patient received the injection 3 years previously. (B) p75NTR neurotrophin receptor immunolabeling shows basal
forebrain cholinergic axons penetrating into the graft (between the parallel lines) in a linear fashion. Scale bar = 25 µm. (C) Nerve growth-factor-expressing neurons
compared with less intense labeling in the nucleus basalis of Meynert neurons located 3 mm from the injection site (D). Scale bar in (C) = 100 µm and in
(D) = 325 µm. Images reproduced from Tuszynski et al. (2015).
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FIGURE 12 | Diagram showing the association between p75NTR and Alzheimer’s-related degenerative signaling networks. Aging, Aβ and other processes produce
numerous changes in signaling pathways involved in neurite and synapse function and degeneration. Degenerative signaling promoted by p75NTR in either its
unliganded state, or in response to proneurotrophin binding to p75NTR and its sortilin family co-receptors, and mediated through one or more receptor adaptors
enables or promotes AD-related degenerative processes. LM11A-31, which interferes with proneurotrophin degenerative signaling and promotes supportive/survival
signaling through p75NTR, reverses many of these AD-associated effects (indicated by •).
FIGURE 13 | Summary diagram showing the changes in the relative levels of NGF-related proteins in the cortex and hippocampus during the progression of AD.
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death in cell culture conditions under which neuronal survival
is dependent on the addition of neurotrophins. These small
molecule ligands effectively acted as positive p75NTR modulators,
inhibited proNGF-induced cell death (Massa et al., 2006) and
blocked binding of proNGF to p75NTR (Tep et al., 2013). Under
these conditions, small molecule ligands could be described as
p75NTR ‘antagonists.’ LM11A-31 has been shown to stimulate
recruitment of interleukin-1 receptor-associated kinase (IRAK)
survival adaptor to p75NTR and to upregulate downstream
NF-κB and Akt pro-survival signaling. Neurotrophic activity and
signaling were absent in cultures using p75NTR−/− neurons
or in the presence of p75NTR-ECD blocking antibody (Massa
et al., 2006). LM11A-31 blocks proNGF-induced degenerative
mechanisms in models of spinal cord injury (Tep et al., 2013),
neurogenic bladder dysfunction (Ryu et al., 2018), and arthritis
(Minnone et al., 2017).
Multiple preclinical studies indicate a role for small
molecule modulation of p75NTR as a therapeutic approach
for slowing progression of AD-related degenerative mechanisms.
Intracellular signaling networks linked to p75NTR have
substantial integration with degenerative signaling networks
implicated in AD (Nguyen et al., 2014). In a model of AD in which
cultured hippocampal neurons are exposed to Aβ oligomers,
LM11A-31 and LM11A-24 inhibited the following Aβ-induced
degenerative mechanisms: activation of calpain/cdk5, GSK3β,
JNK c-Jun, p38 kinase, RhoA; excessive tau phosphorylation; and
inactivation of Akt and CREB (Yang et al., 2008). These ligands
also blocked Aβ-induced neuritic dystrophy and hippocampal
long-term potentiation (LTP) impairment. In studies employing
the hAPPLond/Swe AD mouse model, a once-daily administration
of LM11A-31 over 3 months corrected behavioral deficits
and inhibited neurodegenerative molecular and cellular
pathology including tau phosphorylation and misfolding,
neurite dystrophy, microglial activation and astrocyte activation
(Knowles et al., 2013; Nguyen et al., 2014). However, there was no
effect on lowering soluble Aβ or amyloid plaque levels, consistent
with a mechanism in which modulation of p75NTR inhibits
the ability of Aβ to promote neural degeneration including
tau-related molecular degenerative events and synaptic failure.
The ability of LM11A-31 to reduce measures of microglial
activation in hAPPLond/Swe AD mice was confirmed using
multiple markers of microglial activation as well as micro-PET
imaging using a PET ligand directed to the translocator protein
(TSPO) (James et al., 2017). In hAPPLond/Swe AD mouse studies
employing treatment in late-stage, application of LM11A-31
resulted in a partial reversal of neural degeneration, perhaps
indicative of a particularly robust biological effect (Simmons
et al., 2014). Figure 12 summarizes the ability of the p75NTR
modulator LM11A-31, which interferes with proNT degenerative
signaling and promotes supportive/survival signaling through
p75NTR, to inhibit/reverse AD degenerative mechanisms.
Based on in vivo preclinical studies, a modified formulation
of LM11A-31, as a first-in-class compound directed against
a novel target, was tested in a phase 1 trial in normal
subjects and found to be safe. This compound is currently in
a randomized, double-blinded, phase 2a exploratory endpoint
trial in subjects with mild to moderate AD (NCT03069014).
Treatment is administered via daily oral capsules for 6 months,
and measurements at baseline and post-treatment include
the following: cognitive testing with multiple batteries; MRI
volumetric measures and FDG-PET imaging; and CSF AD core
biomarkers along with biomarkers relevant to target engagement
and mechanisms of action.
CONCLUDING COMMENTS
Figure 13 summarizes the relative changes of NGF upstream
and downstream signaling pathways within the cortex and
hippocampus during the progression of AD. A preponderance
of data indicates that normative levels of NGF and its cognate
receptors are required for the survival and maintenance of
the cholinotrophic system. The preservation of cholinergic
nbM neurons in the face of reduced numbers of TrkA
and p75NTR-positive neurons in MCI and mild AD indicates
that there is not a frank loss of cholinergic perikarya
per se but a phenotypic downregulation of receptor proteins
early in the disease process. Both transcript and protein
data indicate that CBF neuron dysfunction is associated
with an imbalance between TrkA-mediated survival signaling
and proNGF/p75NTR-mediated pro-apoptotic signaling. Despite
these degenerative events, the cholinotrophic system is capable
of cellular resilience and/or neuroplasticity during the prodromal
(DeKosky et al., 2002) and even the later stages of the
disease (Mufson et al., 2012b). In addition to neurotrophic
dysfunction, alterations in nuclear epigenetic proteins occur
within cholinotrophic nbM neurons during the progression of
AD, particularly HDAC2, suggesting a mechanism associated
with changes in transcript expression. Increased proNGF
quantified in postmortem vCSF or premortem lumbar CSF
marked the transition to MCI and to AD, suggesting that this
proneurotrophin is a useful biomarker of disease progression.
Clinical trials provide evidence that NGF gene therapy has the
potential to be a treatment approach for the prevention of
CBF degeneration in AD. Perhaps combining this therapeutic
approach with the development of small molecule agonists to
TrkA to facilitate prosurvival signaling (Jang et al., 2007) or small
molecule antagonists to p75NTR for anti-apoptotic actions should
be added to the treatment toolbox for MCI and AD.
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